Fremanezumab

CHEMBL4297756 Phase 4 Approved Antibody

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

This monthly or quarterly injectable antibody treatment prevents migraines by targeting the calcitonin gene-related peptide (CGRP) pathway, which plays a central role in migraine attacks. It is used as a preventive therapy in adults who experience frequent migraines.

Therapeutic Areas

Migraine Neurology

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

This monthly or quarterly injectable antibody treatment prevents migraines by targeting the calcitonin gene-related peptide (CGRP) pathway, which plays a central role in migraine attacks. It is used as a preventive therapy in adults who experience frequent migraines.

Yes, Fremanezumab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4297756. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.

PillFYI

Looking for patient-friendly information?

Fremanezumab on PillFYI

Quick Data

Synonyms: 1

External Links

ChEMBL CHEMBL4297756

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.